Cart
×
Sarepta Announces FDA Acceptance of Golodirsen (SRP-4053)
SRPT press release – golodirsen NDA acceptance 02 14 19
NS Pharma Community Letter
We are excited that our industry partner, NS Pharma, has applied for accelertated approval for it’s exon 53 skipping therapy, viltolarsen. We applaud the dedication to the Duchenne community by […]
Sarepta Therapeutics Advocacy Newsletter October 2018
Dear Duchenne Advocacy Leaders, Lately we have heard many stop to consider the progress made in the last decade in Duchenne treatment and care. Improvements have been driven by this […]